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Abstract
Interindividual variation in DNA-methylation level is widespread in the human genome, despite its critical role in regulating
gene expression. The nature of this variation, including its tissue-specific nature, and the role it may play in human
phenotypic variation and disease is still poorly characterized. The placenta plays a critical role in regulating fetal growth and
development in ways that have lifelong effects on health. To identify genes with a high degree of interindividual DNA
methylation variation in the human placenta, we surveyed the human genome using the Illumina GoldenGate Methylation
Cancer panel targeting 1505 CpG sites of 807 genes. While many sites show a continuous pattern of methylation levels,
WNT2, TUSC3 and EPHB4 were identified to have a polymorphic ‘‘on-or-off’’ pattern of DNA methylation variation at their
promoter region which was confirmed by pyrosequencing. Methylation of these genes can be found in 7%–25% of over 100
placentas tested. The methylation state at the promoter of these genes is concordant with mRNA allelic expression. In three
informative cases TUSC3 was observed to be methylated on the maternal allele, and it is thus possible this represents a
polymorphically imprinted gene. Furthermore, TUSC3 promoter methylation showed evidence for association with
preeclampsia. A biological significance of these methylation allelic polymorphisms (MAPs) to human placental diversity is
further implied by their placental specificity and absence in mouse. An extended study of blood suggests that MAPs may
also be found in other tissues, implicating their utility for tissue-specific association with complex disorders. The
identification of such ‘‘epipolymorphism’’ in other tissues and their use in association studies, should improve our
understanding of interindividual phenotypic variability and complex disease susceptibility.
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Introduction
Gene expression within various human tissues displays interin-
dividual variability that can contribute to phenotypic variation
[1–3]. Some of this variability is due to DNA sequence differences,
such as single nucleotide polymorphism (SNP) and copy number
variation (CNV) [4], while environmentally mediated or stochastic
effects on epigenetic programming may also affect gene expression
[4]. Investigation of monozygotic twins suggests a genetic
contribution to gene expression variation [5,6]; however, non-
Mendelian inheritance of allelic variation is also observed [7,8]. A
large-scale analysis of allele-specific gene expression showed that
allelic differences in expression level may affect up to 50% of
human genes [9]. As only a small fraction of genetic polymor-
phisms are located in gene regulatory regions, epigenetic variation,
that is independent of local sequence changes, may also contribute
to a significant portion of variation in gene expression.
DNA methylation is a well-characterized form of epigenetic
modification in mammals, and methylation of CpG sites in the
promoter regions of genes can critically affect transcriptional
regulation [10]. However, evidence for a gene silencing effect of
promoter DNA methylation mainly comes from cancer studies,
while this relationship in normal tissues has been less clear [11,12].
Identifying a correlation between gene expression and promoter
methylation compared across normal tissues may be confounded
by the presence of multiple tissue-specific differentially methylated
regions (tDMRs), as well as presence of other tissue-specific
regulatory factors that affect the level of expression [4]. Also, some
tDMRs exhibit a composite methylation pattern, i.e. a mix of
methylated and unmethylated alleles, possibly due to cellular
heterogeneity. Even if DNA methylation silences the promoter
completely, large changes in gene expression level may not be
observed [12]. Thus, identifying distinct DNA methylation
differences among individuals within a particular tissue would be
useful for demonstrating the regulatory role of DNA methylation
on gene expression.
While DNA methylation variation at specific loci, such as
imprinted genes, genes on the X-chromosome and transposable
elements has been reported [13–17], interindividual differences in
DNA methylation for other genes in human tissues is less well-
studied. A genome-wide study of interindividual DNA methylation
variation in the human germline revealed that DNA methylation
differences can be established during development [18]. Skewed
allelic expression associated with sequence-dependent DNA
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the extent of tissue-specific methylation variability, its etiology, and
its role in affecting gene expression variation is needed.
We hypothesize that sequence-independent effects on DNA
methylation set in early development may contribute an additional
layer to human phenotypic variation. In order to identify distinct
DNA methylation differences between individuals and assess the
regulatory role of DNA methylation on gene expression and
phenotypic variation, we surveyed the human genome using the
Illumina GoldenGate Methylation Cancer Panel I. We chose to
study placenta as it plays a vital role in human health due to its
essential role in regulating fetal growth and development and the
long term consequences of in utero development on disease in
adulthood [20]. In addition, placenta has been reported to have
high variability in overall DNA methylation compared to other
tissues as investigated by the same Illumina methylation array
[21], and increased epigenetic variability in the placenta may have
evolved in response to its role in mediating the conflicting
demands of mother and fetus [22]. Although the Illumina
GoldenGate Methylation Cancer panel I targets mainly cancer-
related genes, the pseudomalignant nature of the placenta makes it
suitable for this study [23,24].
Results
Identifying genes with ‘‘on-or-off’’ polymorphic DNA
methylation
Using the Illumina GoldenGate methylation Beadarray, we
initially investigated DNA samples from whole villi (fetus side) of
13 normal placentas (5 female and 8 male) without pregnancy
complication. To identify probes (CpG sites) that have distinct
classes of DNA methylation levels among placentas, we first
calculated the variance of the b-value (proportional to level of
DNA methylation) for each probe. The majority of sites 1210 of
1505, showed very little variability (variance ,0.01) (Figure 1) and
these were generally either always methylated or always
unmethylated. However, the distribution of variances has a broad
tail and many sites showed extremely variable methylation
patterns. While not all CpG sites associated with a single gene
necessarily are expected to be methylated similarly, to reduce the
probability of variability due to technical artefact or to SNPs in the
associated primer sequences, we identified genes for which at least
2 associated CpG sites demonstrated a b-value variance greater
than 1.5 SD from the mean variance for all samples. Using this
criterion, 19 out of 576 genes that had probes targeting two or
more CpG sites were identified as having highly variable DNA
methylation among individual placentas (Figure 2A). Among these
19 genes, 14 genes are located on the autosome while 5 are on the
X chromosome. As expected, methylation at these X-linked sites
(all in gene promoter regions) correlates with sex of the placental
sample (i.e. higher methylation in female than in male) given that
promoter DNA methylation is enriched on the inactive X
chromosome of females [25]. Detection of additional X-linked
genes was limited by our strict criteria for this screen (i.e. two sites,
both .1.5 SD above the mean). WT1, an imprinted gene with
polymorphic imprinting in placenta [26], was detected, which
further validates this approach. Variable DNA methylation
identified at another imprinted gene, MKRN3 (Figure S1A),
suggests it may also be polymorphically imprinted in placenta.
We chose three autosomal genes which had the most
concordant methylation patterns between the two associated
CpG sites assayed for further follow-up: WNT2, EPHB4, and
TUSC3 (Figure 2A). These genes also appeared to have a bimodal
distribution of methylation suggestive of an on/off switch. The
methylation pattern for these genes was confirmed and quantified
more accurately by gene-specific bisulfite pyrosequencing using
primers without any known SNP or CpG site bias (Figure 2B,
Figure S1B). A similar methylation level was found for every CpG
Figure 1. Frequency distribution of DNA methylation variances for 1505 CpG sites in 13 normal placental samples. The average
variance is 0.007. The value for 1.5 SD above the mean variance is 0.025. There are 106 CpG sites with variance greater than 1.5 SD.
doi:10.1371/journal.pone.0007389.g001
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ation in ‘‘methylated’’ cases and almost no methylation in
‘‘unmethylated’’ cases (Figure 2B, Figure S1B). No within-placenta
variability was observed as different sites sampled from the same
placenta always displayed concordant methylation levels (Figure
S2). We further investigated samples from more than 100
placentas by the Illumina array (49 placentas run on separate
Beadarrays than the original set) and bisulfite pyrosequencing (all
placentas). Using the same threshold to search for distinct
methylation polymorphism, 12 genes met the criteria in the
Illumina methylation analysis of the additional 49 placental
samples (Figure S3A). Nine out of the 12 genes, including TUCS3
and WNT2, were in common with those found in the initial
analysis of 13 placental samples. Although EPHB4 did not meet
the variance cut-off observed in the initial set, distinct polymorphic
methylation was observed with 3 of the 49 samples exhibiting a
‘‘methylated’’ state (Figure S3B). The lower variance was thus a
consequence of the lower frequency of ‘‘methylated’’ alleles in the
larger sample set. All samples for the initially identified three CpGs
could be classified as ‘‘methylated’’ or ‘‘unmethylated’’ (i.e. the
distribution of values was again distinctly bimodal) and the
methylation frequency (ratio of number methylated cases to total
number cases) for these genes ranged from 0.07 to 0.25 (Table 1).
Correlation of DNA methylation and gene expression
Since the average methylation level of the CpGs in those
cases classified as ‘‘methylated’’ was close to 50% based on
bisulfite pyrosequencing, we speculated that the DNA methyl-
ation may cause allele-specific v a r i a t i o ni ng e n ee x p r e s s i o n .
Therefore, heterozygous SNPs in the coding regions of these
genes were identified and theg e n o t y p eo fD N Aa n dc D N A
extracted from the same placenta were compared by primer
extension assay (Figure 3, Figure S4). Clonal bisulfite pyrose-
quencing of the WNT2 promoter demonstrated monoallelic
DNA methylation in the methylated cases (Figure 3B). Further-
more, biallelic gene expression was observed in the unmethy-
lated cases, while monoallelic expression was found in the
methylated cases (Figure 3C, Figure S4). A similar observation
was found for EPHB4 (Figure S5). To determine the relationship
between promoter DNA methylation and gene expression, we
identified four cases heterozygous for SNP rs12550009 located
within the 59 UTR of TUSC3 (Figure 4A). Methylation-sensitive
enzyme digestion followed by pyrosequencing genotyping
revealed allele-specific methylation of the ‘‘T’’ alleles in the
two of these cases which were methylated at this gene
(Figure 4D). Genotyping cDNA with pyrosequencing using
RNA-specific RT-PCR primers demonstrated biallelic expres-
Figure 2. Genes exhibiting high interindividual variance in methylation values in the human placentas. (A) Heat-map of 19 genes with
at least 2 probes having methylation variance greater than 1.5 SD from the mean. Probes and sample names are shown and with hierarchical
clustering of beta values based on 1-r (Illumina Beadarray software). A beta value of zero (indicated in bright green) represents an unmethylated locus
and one (indicated in bright red) represents a methylated locus. Probes for genes on the X chromosome are highlighted by a yellow box and the
probes being further investigated here are bolded in blue. (B and C) Validation of variable methylation by bisulfite pyrosequencing for (B) WNT2 and
(C) EPHB4. CpG sites that are targeted by the Illumina probes are highlighted in red. One methylated sample and one unmethylated sample are
shown for each gene. Reference pyrograms are shown on top.
doi:10.1371/journal.pone.0007389.g002
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predominantly expressed in the methylated cases. Thus, lack of
DNA methylation of the gene promoter is correlated with gene
expression. Unlike the sequence-dependent allele-specific DNA
methylation described in another study [19], the present
polymorphic DNA methylation had no correlation with the
genotypes of the SNPs (Table S1). To distinguish this on-off type
of epigenetic polymorphism, we suggest a term called Methyl-
ation Allelic Polymorphism (MAP). This term can generally be
used to apply to any polymorphic methylation, including that
attributable to imprinting or local sequence effects, as well as
that due to other causes (stochastic, environment etc).
Correlation between MAP and pregnancy complication
Intriguingly, the genes exhibiting MAP identified here are
highly expressed in the placenta [27]. Furthermore, WNT2 and
EPHB4, are crucial for placenta development [28–30]. The
variable allelic gene expression caused by MAP may have
functional consequences to placental physiology. In particular,
the expression of TUSC3 was downregulated in trophoblast upon
hypoxic (a characteristic feature in preeclampsia) in vitro culturing
[31]. To determine whether there is a correlation between MAP
and pregnancy disorders, the studied samples were categorized
according to the presence or absence of intrauterine growth
restriction and/or preeclampsia (Table 1). We found a significant
difference in DNA methylation frequency of TUSC3 between
normal and preeclamptic pregnancies (Table 1). Specifically,
TUSC3 promoter methylation was found more frequently in the
late-onset preeclampsia than normal placentas (P=0.02; Fisher’s
test). There was no significant correlation of MAP with maternal
age, gestational age, and fetus gender or birth weight (Table 1).
No conservation of MAP in Ephb4, Tusc3 and Wnt2 of
mice
As we observed no cases exhibiting 100% methylation for any of
these analyzed sites, the MAP is likely regulated in a specific
manner. In order to better understand the regulatory mechanism
as well as the functional effect of MAP, we investigated the
methylation status of these genes in mice, for which embryonic
lethality has been reported in Wnt2 and Ephb4 knock-outs [28,29].
However, the conserved regions of the three genes were
unmethylated in the placentas of 21 outbred mice (Figure 5),
suggesting MAP in these genes may not be conserved in rodent
placenta and implicating a discrepancy of interindividual variation
of these genes between human and mouse placentas. Further
analysis of MAP in other placental mammals would be interesting
to find out if MAP is unique to human placentas.
Tissue-specificity of MAP
To determine the tissue specificity of MAP in human, the fetal
tissues of abortuses with DNA methylation of TUSC3 and WNT2
in the associated placentas were studied. DNA methylation in the
promoter of TUSC3 and WNT2 was not observed in any of 10 fetal
tissues other than placenta (Figure 6). Also, there was no
methylation in the maternal blood cells from women carrying
placentas with DNA methylation of the TUSC3 gene (Figure S7A).
Even within the methylated placenta, trophoblastic chorionic villi
was the only tissue methylated (Figure S7B).
We further tested the genome-wide DNA methylation patterns
in blood cells of 18 normal individuals by the Illumina methylation
array. Using the same criteria as we analyzed in placentas, 15
genes have highly variable methylation in two associated CpGs
(defined as .1.5 SD above the mean) (Figure S8A). 14 of the
identified genes were located on the X chromosome, indicating
that blood cells are less variably methylated than placenta, which is
consistent with a previous study [21]. As expected, we found no
MAP in EPHB4, TUSC3 and WNT2 (Figure S8B). Two distinct
CpGs associated with TRIP6 genes were identified with highly
variable methylation, while CpGs associated with two other genes,
NOD2 and ALOX12, nearly met these criteria. While the variation
was not distributed in a clearly bimodal fashion, the levels of
methylation for each pair of CpGs showed a very high degree of
correlation, suggesting this is not methodological (measurement
error or sequence variants directly affecting probe binding). The
variable methylation at NOD2 was further confirmed by
pyrosequencing (Figure S8C). A high degree of allelic variation
of NOD2 expression has been reported elsewhere [32], suggesting
this variable methylation reflects this variable expression. As whole
blood consists of a mixture of various types of cells, distinct on/off
methylation patterns confined to a specific cell type may appear to
be continuously distributed due to confounding by the varying
proportions of cells among individuals. Analysis of individual
blood cell populations would be necessary to determine if this is
the case for these genes.
Table 1. Correlation between MAP and clinical status.
Gene Name M/U Total MF MA (year) GA (week) BW (g)
Gender
(M:F) IUGR No IUGR p-value EOPET LOPET No PET p-value
EPHB4 M 9 0.07 33.0 36.9 2878.3 4:5 2 7 1.00 1 1 7 1.00
U 115 34.6 36.9 2802.0 56:59 30 85 15 17 83
TUSC3 M 31 0.25 34.5 36.2 2776.7 15:16 10 21 0.48 3 9 19 ,0.05
U 91 34.3 37.1 2836.3 48:43 22 69 13 9 69
WNT2 M 25 0.20 33.6 37.7 3100.7 12:13 3 22 0.08 1 4 20 0.37
U 97 34.7 36.6 2715.5 46:51 29 68 15 14 68
M=Methylated;
U=Unmethylated;
MF=Methylation frequency (Number of methylated cases/Total number of cases);
MA=Maternal age;
GA=gestational age;
BW=birth weight;
EOPET=early onset preeclampsia (,34 weeks’ gestation);
LOPET=late onset preeclampsia ($34 weeks’ gestation).
doi:10.1371/journal.pone.0007389.t001
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Understanding the source of phenotypic variation among
individuals is a fundamental aspect of human biology. Current
studies mainly focus on searching for genetic sequence variation
which might miss the important phenotypic effects exerted by
epigenetic polymorphisms. A study of the MHC locus on
chromosome 6 in 7 human tissues across 32 individuals showed
that around half of the studied loci had some interindividual
variability for DNA methylation in at least one tissue [33].
However, this was not extensively quantified and its effect on gene
expression was not investigated. Other loci with variable DNA
methylation have also been found recently [18,19], but most, if not
all, are dependent on DNA sequence variation within the
differentially methylated region. In this report, we identify tissue-
specific DNA methylation polymorphisms that can be found in as
many as 25% of individuals and cannot simply be explained by the
DNA sequence differences generated by common flanking SNPs.
They are sequence-independent epigenetic polymorphisms that
can act as a cis-acting regulator of gene expression.
The silencing effect of DNA methylation on single allele in
EPHB4, TUSC3 and WNT2 resembles the characteristic of
imprinted genes. With limited parental DNA and RNA samples
from the ‘‘methylated’’ cases, we were unable to rule out the
possibility that the genes with MAP are novel polymorphic
imprinted genes. Polymorphic imprinting has been reported in
humans for IGF2R (paternal or biallelic expression) [34] and WT1
(maternal or biallelic expression) [26]. By screening 70 maternal-
fetal pairs for rs1250009 in TUSC3, we identified three cases
informative for parental origin of the methylation and all three were
Figure 3. Allele-specific DNA methylation and mRNA expression of WNT2. (A) Schematic of the WNT2 locus showing the regions
investigated by clonal bisulfite pyrosequencing of the promoter (2493 to 2449 relative to the transcriptional start site according to NM_003391) and
genotyping assays within exon 5. PCR primers for DNA and cDNA genotyping by iPlex are indicated by black arrows while RT-PCR primers for mRNA
genotyping are indicated by arrows highlighted in white. (B) Bisulfite pyrosequencing of single clones from four placental samples. The A/G
polymorphism of SNP rs39315 is indicated. Each row represents one clone and each circle represents one CpG. Methylated CpGs are shown in black
while unmethylated CpGs are shown in white. The presence of a cytosine proximal to this A/G SNP site creates a polymorphic CpG site. (C) Allele-
specific expression of WNT2 based on the analysis of the A/G allele of rs2228946 in DNA and cDNA by iPlex. Peak height of the alleles corresponds to
the relative amount of alleles present in the sample. (D) Validation of allele-specific expression of WNT2 by cDNA-specific primers. Double peaks are
observed in unmethylated samples while single peaks are found in methylated samples.
doi:10.1371/journal.pone.0007389.g003
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investigated by bisulfite pyrosequencing on the promoter (2105 to 257 relative to the transcriptional start site according to NM_006765) and
genotyping assays of the 59 untranslated region. PCR primers for DNA genotyping are indicated by black arrows while RT-PCR primers for mRNA
genotyping are indicated by arrows highlighted in white. Enzyme recognition sites for BstUI are indicated by ‘‘B’’. (B) Methylation status of TUSC3
promoter region studied by bisulfite pyrosequencing. A similar methylation level of every CpG within each sample is observed and the gene follows
‘‘on-or-off’’ methylation pattern. Each circle represents a CpG site in a sample. Area shaded in black is proportional to the methylation level of the
CpG site indicated by pyrosequencing. (C) Validation of complete methylation-sensitive restriction enzyme digestion on unmethylated molecules.
Genomic DNA was predigested with BstUI followed by PCR amplification with TUSC3 and ID2 specific primers (Table S2). BstUI digestion sites within
the ID2 region were unmethylated (Figure S6) and, therefore, no PCR product was generated after enzyme digestion. (D) Allele-specific methylation of
TUSC3 on the fragment containing SNP rs12550009 demonstrated by enzyme digestion pyrosequencing. The ‘‘Simplex’’ diagrams (top) show the
reference pyrograms by genotype. A heterozygous CT in the methylated samples (PM55 and PM123) displays a homozygous T pattern after BstUI
digestion indicating predominant methylation of the T allele. Allele-specific mRNA expression is concordant with allele-specific methylation on the
same SNP rs1250009. Predominant expression of C alleles was observed in the cDNAs generated by RNA specific primers (bottom). RT+ and RT2
represent assays with Reverse Transcriptase and without Reverse Transcriptase, respectively.
doi:10.1371/journal.pone.0007389.g004
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PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7389Figure 5. DNA methylation status of MAP conserved regions in mouse. Schematic of (A) Ephb4 locus (310 to 477 relative to the
transcriptional start site according to NM_010144), (B) Tusc3 locus (250 to 139 relative to the transcriptional start site according to NM_030254) and
(C) Wnt2 locus (2292 to 2176 relative to the transcriptional start site according to NM_003391), showing the regions investigated by bisulfite
pyrosequencing. Sequence alignments on bisulfite converted DNA between human and mouse at the first 60 nucleotides including the sequencing
primers are shown. Sequences highlighted in red are the nucleotides being investigated while the nucleotides highlighted in blue are the differences
between them. Reference pyrograms are provided and one representative sample for each locus is shown. (D) Summary of methylation level at
Ephb4, Tusc3 and Wnt2 in 21 outbred mice. No ‘‘on-or-off’’ methylation variation is found in the mouse conserved regions.
doi:10.1371/journal.pone.0007389.g005
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‘‘methylated’’ case of EPHB4 with paternal expression suggesting the
maternal allele was methylated in this case. While the MAPs were
maternally methylated in all informative cases we identified, we
cannot rule out the possibility that this happened only by chance
due to the small sample size. Of the roughly 80 imprinted loci
identified to date, few are imprinted in human but not in mouse
[35].Thus these results could be consistent with an abnormal or
stochastic failure of erasure of this ‘‘imprint’’ in the trophoblastic villi
or specifically to a failure to erase a maternal methylation mark.
Alternatively, there may be a lineage-specific acquisition of
DNA methylation by a de novo mechanism early in development. In
this case, either allele could be methylated, or there may be a
preference for acquiring methylation on one parental allele due to
other epigenetic marks differentiating the two parental chromo-
somes. It is possible that a random acquisition of DNA
methylation on single allele of these genes reflects a selection for
reduced expression of these genes which may be relevant to the
generation of imprinted genes during evolution [36]. Further
investigation of parental origins of the allelic methylation is needed
to test this hypothesis.
The fact that none of the cases in this study has complete
methylation on both alleles suggested that the regulation of
developmental important genes by MAP in placenta is functionally
significant. The correlation of TUSC3 promoter methylation with
preeclampsia, a pregnancy disorder that is complicated by
placental hypoxia implies a biological relevance to MAP. TUSC3
is an ortholog of the yeast Ost3 protein which catalyzes the transfer
of an oligosaccharide chain on nascent proteins in the process of
N-glycosylation [37]. While the function of TUSC3 in placenta is
unknown, its paralog, MAGT1, is believed to be associated with
embryonic implantation and hypertension [38]. In addition,
TUSC3 is highly expressed in the human placenta, but expression
was reduced after in vitro hypoxic culturing of trophoblast [31].
These observations suggest that TUSC3 may be important in the
development of preeclampsia. Further studies are necessary to
confirm this association and to identify the intrinsic function of
TUSC3 in the human placenta and its relation to preeclampsia
Figure 6. Tissue-specific DNA methylation of WNT2 and TUSC3. (A) DNA samples from two independent fetuses associated with placental
methylation at the WNT2 promoter were investigated by bisulfite pyrosequencing. None of the tissues (lung, kidney, adrenal, heart and liver) other
than placenta was methylated. (B) DNA samples from two independent fetuses with placental methylation at the TUSC3 promoter were investigated
by bisulfite pyrosequencing. None of the tissues (lung, kidney, gut, muscle, brain, thymus and testis) other than placenta was methylated. Each circle
represents a CpG site in a sample. Area shaded in black is proportional to the methylation level of the CpG site indicated by pyrosequencing.
doi:10.1371/journal.pone.0007389.g006
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appear to be related to the methylation pattern of EPHB4 and
WNT2 in human, a phenotypic effect of these MAP genes on the
human placenta cannot be excluded as only two clinical features,
IUGR and preeclampsia were evaluated.
The discrepancy of DNA methylation profile between human
and mouse might also suggest an evolutionary role. Several DNA
methylation studies of placenta revealed a number of tumor-related
genes specifically methylated in the human placenta [23,24]. It is
believed that the difference in DNA methylation profile between
rodents and primates may account for the disparity of placentation,
such as different degree of trophoblast invasiveness, between
species. Intriguingly, EPHB4 and WNT2 were found to be
responsible for vascularisation of placenta which associated with
the invasion of spiral arteries [28,30]. It is possible that the DNA
methylation polymorphism in these genes causes a subtle difference
in the degree of trophoblast invasiveness among individual human
placentas. Many of the other genes detected in our initial screen
likewise may play an important role in placentation (Figure 2). For
example CTGF is an important regulator of VEGF, a factor critical
in vascularisation of the placenta and decidua [39]. However,
biological effects may be difficult to discern when considering only
the methylation status of individual genes as it may be the combined
effects of multiple genes that is critical in development of traits,
which may explain the marginal significance of disease association
for TUSC3. The identification of MAP in other genes could be
tested for association with complex traits by whole-epigenome
association studies [40,41].
Recently, ‘‘epimutation’’ has been found for MLH1 and MSH2
in cancer patients [42,43]. Similar to the MAP identified here,
epimutation can silence the genes in an allelic-specific manner.
The distinction is that MAP is more frequent and appears to be set
early in development, as we observed no within-placenta
heterogeneity and found MAP even in first-trimester placentas
(Data not shown). Although additional biological effects of such
‘‘epipolymorphism’’ in human remains to be determined, the
functional consequence of imbalanced allelic gene expression is
substantial [44,45]. A genome-wide study of gene expression found
that the variation of gene expression between alleles is common in
human and it is believed to be the basis for variation in the
transmission of some diseases [9,32]. Thus the study of MAP as a
method of identifying allelic expression differences, through
measures at the DNA level, should open up a new dimension
for future disease association studies. The Illumina methylation
array used in this study only targets 807 genes, of which we only
considered the limited set of those with multiple CpGs exhibiting
correlated methylation patterns. Looking at these same genes more
exhaustively, and considering the more than 20,000 genes in the
human genome, there should be many more genes identified with
MAP which might contribute to the disease susceptibility in a
multifactorial and tissue-specific way. The future study of MAP is
important for our understanding of interindividual phenotypic
variability, as well as complex disease susceptibility.
Materials and Methods
Sample collection
This study was approved by the ethics committees of the
University of British Columbia and the Children’s & Women’s
Health Centre of British Columbia. Samples from 128 placenta
were collected from Vancouver BC Children’s & Women’s
Hospital with informed consent from individuals. Clinical
information was collected on prenatal findings, pregnancy
complications and birth parameters (gestational age, sex, birth
weight etc). Preeclampsia was defined as at least two of the
following: (1) hypertension (systolic blood pressure $140 mmHg
and/or diastolic blood pressure $90 mmHg, twice, .4 h apart)
after 20 weeks, and proteinuria defined as $0.3 g/d or $2+
dipstick proteinuria after 20 weeks, (2) non-hypertensive and non-
proteinuric HELLP syndrome or (3) an isolated eclamptic seizure
without preceding hypertension or proteinuria. Intrauterine
growth retardation (IUGR) was defined as either (1) birth weight
,3rd percentile for gender and gestational age using Canadian
charts, or (2) birth weight ,10th percentile with either: (a)
persistent uterine artery notching at 22+0t o2 4 +6 weeks gestation,
(b) absent or reversed end diastolic velocity on umbilical artery
Doppler, and/or (c) oligohydramnios (amniotic fluid index
,50 mm). At least two sites were sampled from each placenta.
DNA was extracted and RNAlater (Qiagen) was added for follow
up RNA extraction. First-trimester normal placental tissues,
peripheral blood samples from normal individuals and fetal tissue
biopsies from abortuses were obtained with review board approval
and were anonymous to individual identifiers. Outbred mouse
placental tissues were obtained from pregnant mice with
institutional animal ethics approval.
DNA methylation analysis
Bisulfite modification of 500 ng of genomic DNA was
performed using the EZ DNA Methylation Kit (Zymo Research)
according to the manufacturer instructions. After bisulfite
treatment, DNA samples were subjected to the Illumina Gold-
enGate methylation Cancer Panel I array-based assay, using
Illumina-supplied reagents and conditions. A b-value of 0 to 1 was
reported for each CpG site, signifying the percentage of
methylation, from 0% to 100%. b-values were calculated by
subtracting background with use of negative controls on the array
and taking the ratio of the methylated signal intensity to the sum of
both methylated and unmethylated signals.
To identify genes with the most highly variable distribution of
methylation values, the variance of b-values among placentas was
calculated for each CpG site, as well as the standard deviation of this
valuerelative tothe meanvariance observed forall CpGs.Those sites
with variance values .1.5 standard deviation from the mean were
considered to be ‘‘highly variable’’. To then select for findings not
likely to be due to artefact (such as variable hybridization or local
sequence variants), only genes with at least two associated highly
variable CpGs were considered. The identified pairs of highly
variable CpGs associated with the same gene tended to show a good
degree of correlation of methylation values and several appeared to
have a bimodal distribution in methylation values suggestiveof on/off
methylation. Four autosomal genes which had the highest correlation
in methylation values between the two associated CpGs were selected
for follow-up confirmation. Methylation-unbiased PCR and sequenc-
ing primers were designed based on the sequences from Illumina
probes on the CpG site (Table S2). Pyrosequencing was performed
on a Biotage PSQ HS96 Pyrosequencer and the quantitative levels of
methylation for each CpG dinucleotide were evaluated with Pyro Q-
CpG software (Biotage). A test run for each assay was performed in
triplicate to confirm reproducibility. For clonal bisulfite pyrosequen-
cing, PCR product from individual samples was generated by non-
biotinated primers (Table S2) and subsequently TA-cloned into
pGEM-Teasy vector (Promega). Individual clones were picked and
analyzed by pyrosequencing as described.
SNP genotyping
Multiplex genotyping on genomic DNA was performed by iPlex
(Sequenom) in Quebec Genome Centre. Primer sequences for
individual SNP genotyping are available upon request. The primer
Placental Epipolymorphism
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by mass spectrometric detection using the MassARRAY Compact
system (Sequenom). For BstUI predigestion assay followed by
pyrosequencing on TUSC3, 200 ng of genomic DNA was digested
with 100 units of BstUI (New England Biolabs) for 18 hours. 20 ng
was used for PCR and ID2 was used as internal control for
validation of complete enzyme digestion in each sample.
Pyrosequencing was performed on a Biotage PSQ HS96
Pyrosequencer and the relative levels of allele for the SNP were
evaluated with PSQ96MA SNP analysis software (Biotage).
Genotyping on mRNA was carried out either with cDNA
prepared using Omniscript Reverse Transcriptase Kit (Qiagen)
followed by iPlex (Sequenom) or one step RT-PCR (Qiagen)
followed by sequencing or pyrosequencing. Primers for the one
step RT-PCR assays were designed to span at least one intron
(Table S2). PCR without reverse transcriptase was performed on
each sample to confirm no genomic DNA contamination.
Statistical Analysis
All the statistical analysis in this study was performed using
VassarStats (http://faculty.vassar.edu/lowry/VassarStats.html).
Supporting Information
Figure S1 Validation of variable methylation at (A) MKRN3
and (B) TUSC3 by pyrosequencing. Pyrograms from one
methylated sample and one unmethylated sample are shown.
Reference pyrograms are shown on top. Methylation level of CpG
sites that are targeted by the Illumina probes are highlighted in
red.
Found at: doi:10.1371/journal.pone.0007389.s001 (0.03 MB GIF)
Figure S2 Intraindividual variability of DNA methylation on
MAP. DNA methylation level of (A) TUSC3, (B) EPHB4 and (C)
WNT2 is given for multiple whole villous samples taken from the
same placenta (four sites for PM55, two sites for PM94). On-or-off
DNA methylation pattern was consistent from different samples
within the same placenta. Each circle represents a CpG site within
a sample. The area shaded in black is proportional to the
methylation level of the CpG site indicated by pyrosequencing.
Found at: doi:10.1371/journal.pone.0007389.s002 (0.08 MB GIF)
Figure S3 Genes exhibiting high interindividual variance in
methylation values in a large population of human placentas. (A)
Heat-map of 12 genes with at least 2 probes having methylation
variance greater than 1.5 SD from the mean. Probes and sample
names are shown and with hierarchical clustering of beta values
based on 1-r (Illumina Beadarray software). A beta value of zero
(indicated in bright green) represents an unmethylated locus and
one (indicated in bright red) represents a methylated locus. Probes
for genes on the X chromosome are highlighted by a yellow box.
(B) Heat-map of EPHB4 in 49 human placentas.
Found at: doi:10.1371/journal.pone.0007389.s003 (0.14 MB GIF)
Figure S4 Allele-specific mRNA expression in WNT2. (A)
Schematic of WNT2 locus showing the regions investigated by
genotyping assays within exon 5 of 3 methylated samples and 3
unmethylated samples. PCR primers for DNA and cDNA
genotyping by Sequenom are indicated by black arrows. (B) Allele-
specific expression of WNT2 is observed based on the A/G allele of
rs2228946 in DNA and cDNA by iPlex. Peak height of the alleles
corresponds to the relative amount of alleles present in the sample.
Found at: doi:10.1371/journal.pone.0007389.s004 (0.04 MB GIF)
Figure S5 Allele-specific methylation and mRNA expression in
EPHB4. (A) Schematic of the EPHB4 locus showing the regions
investigated by clonal bisulfite pyrosequencing on the exon 1 (58 to
153 relative to the transcriptional start site according to
NM_004444) and genotyping assays for exon 10. PCR primers
for DNA by sequencing are indicated by black arrows while RT-
PCR primers for mRNA genotyping are indicated by arrows
highlighted in white. (B) Bisulfite pyrosequencing of single clones
from four placenta samples. Each row represents one clone and
each circle represents one CpG. Methylated CpGs are shown in
black while unmethylated CpGs are shown in white. (C) Allele-
specific expression of EPHB4 at A/G allele of rs314359 in DNA
and cDNA by sequencing. Double peaks are shown in unmethy-
lated samples. However, peaks on the SNP were skewed only in
cDNA from methylated samples.
Found at: doi:10.1371/journal.pone.0007389.s005 (0.09 MB GIF)
Figure S6 CpG methylation status of ID2 on BstUI digestion
sites. Schematic of ID2 locus showing the regions investigated by
bisulfite pyrosequencing is shown on top (8 to 186 relative to the
transcriptional start site according to NM_002166). PCR primers
for bisulfite pyrosequencing are indicated by black arrows.
Enzyme digestion sites of BstUI are indicated by ‘‘B’’. Reference
pyrogram is provided. CpG sites were unmethylated for this region
of ID2 in the 4 samples investigated.
Found at: doi:10.1371/journal.pone.0007389.s006 (0.03 MB GIF)
Figure S7 Tissue-specific DNA methylation of TUSC3. (A)
DNA samples from two independent fetuses with placentas
unmethylated in TUSC3 promoter were investigated by bisulfite
pyrosequencing. None of the cases were methylated in other
tissues. (B) DNA samples from 3 independent placentas with
trophoblastic villi methylated in TUSC3 promoter were investi-
gated by bisulfite pyrosequencing. None of the tissues (Aminon,
chorion, cord, decidua and maternal blood) other than whole villi
was highly methylated. Each circle represents a CpG site in a
sample. Area shaded in black is proportional to the methylation
level of the CpG site indicated by pyrosequencing.
Found at: doi:10.1371/journal.pone.0007389.s007 (0.12 MB GIF)
Figure S8 Interindividual variance of methylation values in the
human blood cells. (A) Heat-map of 14 genes with at least 2 probes
having methylation variance greater than 1.5 SD from the mean.
Probes and sample names are shown and with hierarchical
clustering of beta values based on 1-r (Illumina Beadarray
software). A beta value of zero (indicated in bright green)
represents an unmethylated locus and one (indicated in bright
red) represents a methylated locus. Probes for genes on the X
chromosome are highlighted by a yellow box. (B) Heat-map of
EPHB4, TUSC3, WNT2 and NOD2 (CARD15) in human blood
generated by Illumina GoldenGate Methylation Array. (C)
Validation of variable methylation of NOD2 by bisulfite
pyrosequencing. Schematic of NOD2 locus showing the regions
investigated by bisulfite pyrosequencing (2323 to 2266 relative to
the transcriptional start site according to NM_022162). One
methylated sample and one unmethylated sample are shown.
Reference pyrograms are shown on top. Methylation level on
CpG sites that targeted by the Illumina probe is highlighted in red.
Found at: doi:10.1371/journal.pone.0007389.s008 (0.10 MB GIF)
Table S1 Genotypes at single nucleotide polymorphisms asso-
ciated with EPHB4,TUSC3, and WNT2 show no association with
methylation status of the identified MAP for the same gene.
Found at: doi:10.1371/journal.pone.0007389.s009 (0.03 MB
XLS)
Table S2 PCR primers and conditions for all assays.
Found at: doi:10.1371/journal.pone.0007389.s010 (0.03 MB
XLS)
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